Kisunla

News

Most patients "won't see benefit" with Alzheimer's drugs

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

News

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Eisai moves swiftly to expand subcutaneous Leqembi label

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

Dose-at-home Leqembi for Alzheimer's cleared in US

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

Lilly's appeal unlocks EU approval of Alzheimer's drug

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.

News

FDA clears new, safer regimen for Lilly's Alzheimer's drug

Eli Lilly has won FDA approval for a new regimen for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of side effects.

Most patients "won't see benefit" with Alzheimer's drugs

Appeal finds NICE must reconsider Alzheimer's drugs

Eisai moves swiftly to expand subcutaneous Leqembi label

Dose-at-home Leqembi for Alzheimer's cleared in US

Lilly's appeal unlocks EU approval of Alzheimer's drug

FDA clears new, safer regimen for Lilly's Alzheimer's drug

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Kisunla

Editor's Picks